This article is more than 5 years old. Information may no longer be current.

Intravitreal anti-VEGF may be effective in treating polypoidal choroidal vasculopathy

Retina. 2011;31(5):846-856.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Intravitreal bevacizumab may improve visual acuity and macular exudative changes in patients with polypoidal choroidal vasculopathy, according to a study.

The retrospective study included 35 eyes of 33 patients who were treated with 2.5 mg of Avastin (bevacizumab, Genentech) at baseline, monitored monthly for changes in best corrected visual acuity and central retinal thickness, and given additional injections on an as-needed basis. Each patient received a mean of 3.3 injections over a 1-year period.

Mean BCVA improved from 0.79 ± 0.42 logMAR at baseline to 0.67 ± 0.51 logMAR at 12 months, and central retinal thickness improved from a baseline mean of 297 ± 94 µm to 221 ± 61 µm. At the study's conclusion, indocyanine green angiography showed five of 31 eyes with completely resolved polyps and 10 of 31 eyes with reduced polyps.

No systemic or severe local complications were observed; however, the study authors classified lack of a control group, unfixed treatment intervals, study design and number of patients as potential limitations.